Key Objectives
- Understand how AI, automation, and high-throughput process development can reduce risk and accelerate early- and late-phase biologics manufacturing.
- Identify the role of digitization, inline analytics, and quality-by-design principles in enabling scalable and regulatory-ready bioprocesses.
- Evaluate how standardized manufacturing facilities can improve supply chain resilience and support commercial production.
Biologics development carries inherent risk, particularly in early phases where funding constraints make speed, cost reduction, and efficient process development critical. High-throughput experimentation, automation, and AI-driven tools are increasingly being applied to bioreactor monitoring, inline analytics, and experimental design to enable faster development while supporting scalable, quality-by-design processes. Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, discusses how harmonized manufacturing facilities and end-to-end digitization are further reducing supply chain risk and enabling agile, global commercial manufacturing.
